Voyager Therapeutics Profit Margin

The latest profit margin for VYGR is -3.2% as of March 2026. That compares with -1.26% in the prior-year period — down 152.7% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Voyager Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, VYGR's profit margin moved from -1.26% to -3.2% — a 152.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Voyager Therapeutics's valuation or profitability profile.

Against Healthcare companies, VYGR currently prints -3.2% for profit margin, while the sector average sits near 15.58%. That is roughly 2150.9% below the sector mean. Large gaps often invite a closer look at Voyager Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Voyager Therapeutics converts resources into returns. At -3.2%, VYGR may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1.26% in the prior-year period — down 152.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VYGR's profit margin (-3.2%), review year-over-year change from -1.26%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.